Les complications sont rares, la plupart des cas étant asymptomatiques et sans incidents.
FréquenceComplications
#5
Y a-t-il des complications post-chirurgicales ?
Oui, des complications comme des infections ou des saignements peuvent survenir après la chirurgie.
ChirurgieComplications post-opératoires
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs de risque ne sont pas bien définis, mais des antécédents familiaux peuvent être impliqués.
Facteurs de risqueAntécédents familiaux
#2
L'exposition à des toxines augmente-t-elle le risque ?
Aucune preuve solide ne lie l'exposition à des toxines au développement de l'hémangiome sclérosant.
ToxinesRisque
#3
Les antécédents médicaux influencent-ils le risque ?
Les antécédents médicaux ne semblent pas avoir d'impact direct sur le développement de cette tumeur.
Antécédents médicauxRisque
#4
Le tabagisme est-il un facteur de risque ?
Le lien entre tabagisme et hémangiome sclérosant n'est pas clairement établi dans la littérature.
TabagismeRisque
#5
Les facteurs génétiques jouent-ils un rôle ?
Des études suggèrent que des facteurs génétiques peuvent influencer le développement de l'hémangiome.
Facteurs génétiquesHémangiome
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémangiome sclérosant du poumon : Questions médicales les plus fréquentes",
"headline": "Hémangiome sclérosant du poumon : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémangiome sclérosant du poumon : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-17",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs du poumon",
"url": "https://questionsmedicales.fr/mesh/D008175",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du poumon",
"code": {
"@type": "MedicalCode",
"code": "D008175",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.785.520"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon",
"alternateName": "Pulmonary Sclerosing Hemangioma",
"code": {
"@type": "MedicalCode",
"code": "D047868",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Weidong Zhang",
"url": "https://questionsmedicales.fr/author/Weidong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Cardiothoracic Surgery, Henan Provincial Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, Henan, China. zhangweidong0371@126.com."
}
},
{
"@type": "Person",
"name": "Tae Wook Kang",
"url": "https://questionsmedicales.fr/author/Tae%20Wook%20Kang",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dong Ik Cha",
"url": "https://questionsmedicales.fr/author/Dong%20Ik%20Cha",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Seong Hyun Kim",
"url": "https://questionsmedicales.fr/author/Seong%20Hyun%20Kim",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dan Song",
"url": "https://questionsmedicales.fr/author/Dan%20Song",
"affiliation": {
"@type": "Organization",
"name": "Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Modeling Low Muscle Mass Screening in Hemodialysis Patients.",
"datePublished": "2022-10-21",
"url": "https://questionsmedicales.fr/article/36273447",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000526866"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fat-Free Mass Index as a Surrogate Marker of Appendicular Skeletal Muscle Mass Index for Low Muscle Mass Screening in Sarcopenia.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36179769",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jamda.2022.08.016"
}
},
{
"@type": "ScholarlyArticle",
"name": "The dilemma of recalling well-circumscribed masses in a screening population: A narrative literature review and exploration of Dutch screening practice.",
"datePublished": "2023-05-03",
"url": "https://questionsmedicales.fr/article/37169601",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.breast.2023.05.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology.",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35971172",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-022-08394-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "The efficacy of mass screening for chronic obstructive pulmonary disease using screening questionnaires in a medical health check-up population.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36057534",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.resinv.2022.07.005"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012142"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du poumon",
"item": "https://questionsmedicales.fr/mesh/D008175"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hémangiome sclérosant du poumon",
"item": "https://questionsmedicales.fr/mesh/D047868"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémangiome sclérosant du poumon - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémangiome sclérosant du poumon",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémangiome sclérosant du poumon",
"description": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?\nQuels examens sont recommandés pour confirmer le diagnostic ?\nLes symptômes influencent-ils le diagnostic ?\nPeut-on confondre cette tumeur avec d'autres lésions ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Mass+Screening#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémangiome sclérosant du poumon",
"description": "Quels sont les symptômes courants de l'hémangiome sclérosant ?\nL'hémangiome sclérosant cause-t-il des difficultés respiratoires ?\nPeut-on avoir des symptômes sans lésion visible ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Mass+Screening#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémangiome sclérosant du poumon",
"description": "Peut-on prévenir l'hémangiome sclérosant du poumon ?\nY a-t-il des facteurs de risque connus ?\nLes habitudes de vie influencent-elles le risque ?\nLes examens réguliers aident-ils à la détection précoce ?\nLes femmes sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Mass+Screening#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémangiome sclérosant du poumon",
"description": "Quel est le traitement standard pour l'hémangiome sclérosant ?\nPeut-on traiter cette condition par des médicaments ?\nQuand est-il nécessaire de surveiller sans traiter ?\nQuels sont les risques associés à la chirurgie ?\nY a-t-il des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Mass+Screening#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémangiome sclérosant du poumon",
"description": "Quelles complications peuvent survenir ?\nL'hémangiome peut-il se transformer en cancer ?\nComment gérer les complications respiratoires ?\nLes complications sont-elles fréquentes ?\nY a-t-il des complications post-chirurgicales ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Mass+Screening#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémangiome sclérosant du poumon",
"description": "Quels sont les principaux facteurs de risque ?\nL'exposition à des toxines augmente-t-elle le risque ?\nLes antécédents médicaux influencent-ils le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Mass+Screening#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, notamment la tomodensitométrie (TDM) et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La TDM thoracique et l'IRM peuvent aider à visualiser la lésion et son caractère bénin."
}
},
{
"@type": "Question",
"name": "Les symptômes influencent-ils le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être absents, rendant le diagnostic souvent incident lors d'examens pour d'autres raisons."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette tumeur avec d'autres lésions ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres tumeurs pulmonaires, nécessitant une analyse approfondie."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet de confirmer la nature bénigne de la lésion et d'exclure d'autres pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hémangiome sclérosant ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, il peut provoquer une toux ou des douleurs thoraciques dans certains cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome sclérosant cause-t-il des difficultés respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des complications peuvent entraîner des difficultés respiratoires dans certains cas."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans lésion visible ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes peuvent survenir sans lésion visible, rendant le diagnostic plus complexe."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes ne varient pas significativement selon l'âge, car la plupart des cas sont asymptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez la toux persistante ou des douleurs thoraciques, bien que souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hémangiome sclérosant du poumon ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de mesures préventives spécifiques pour cette condition bénigne."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas clairement établis, mais des antécédents familiaux peuvent jouer un rôle."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve directe ne lie les habitudes de vie au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la détection précoce ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers peuvent aider à détecter des anomalies, mais l'hémangiome est souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent une prévalence plus élevée chez les femmes, mais les données sont limitées."
}
},
{
"@type": "Question",
"name": "Quel est le traitement standard pour l'hémangiome sclérosant ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est généralement chirurgical si la tumeur est symptomatique ou suspecte."
}
},
{
"@type": "Question",
"name": "Peut-on traiter cette condition par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement médicamenteux spécifique, la chirurgie est la principale option."
}
},
{
"@type": "Question",
"name": "Quand est-il nécessaire de surveiller sans traiter ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Si la tumeur est asymptomatique et bénigne, une surveillance régulière peut suffire."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés à la chirurgie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des saignements et des complications respiratoires post-opératoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements alternatifs ne sont pas prouvés efficaces et ne remplacent pas la chirurgie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections pulmonaires et des hémorragies dans de rares cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome peut-il se transformer en cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'hémangiome sclérosant est une tumeur bénigne et ne se transforme pas en cancer."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications respiratoires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications respiratoires doivent être traitées symptomatiquement et surveillées attentivement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, la plupart des cas étant asymptomatiques et sans incidents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications post-chirurgicales ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des infections ou des saignements peuvent survenir après la chirurgie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas bien définis, mais des antécédents familiaux peuvent être impliqués."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve solide ne lie l'exposition à des toxines au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents médicaux ne semblent pas avoir d'impact direct sur le développement de cette tumeur."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le lien entre tabagisme et hémangiome sclérosant n'est pas clairement établi dans la littérature."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que des facteurs génétiques peuvent influencer le développement de l'hémangiome."
}
}
]
}
]
}
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Computed tomography (CT) can accurately measure muscle mass, which is necessary for diagnosing sarcopenia, even in dialysis patients. However, CT-based screening for such patients is challenging, espe...
Hemodialysis patients (n = 619) who had undergone abdominal CT screening were divided into the development (n = 441) and validation (n = 178) groups. PMI was manually measured using abdominal CT image...
Of all subjects, 226 (37%) were diagnosed with low muscle mass using PMI. A predictive model for low muscle mass was calculated using ten variables: each grip strength, sex, height, dry weight, primar...
Our results facilitate skeletal muscle screening in hemodialysis patients, assisting in sarcopenia prophylaxis and intervention decisions....
We aimed to examine the relationship between the fat-free mass index (FFMI; FFM/height...
Cross-sectional study....
This study included 1313 adults (women, 33.6%) aged 40-87 years (mean age, 55 ± 10 years) from the WASEDA'S Health Study....
Body composition was measured using multifrequency BIA and DXA. Low muscle mass was defined according to the criteria of the Asian Working Group for Sarcopenia 2019....
BIA-measured FFMI showed strong positive correlations with both BIA- (r = 0.96) and DXA-measured (r = 0.95) ASMIs. Similarly, in the subgroup analysis according to age and obesity, the FFMI was correl...
The FFMI showed a strong positive correlation with BIA- and DXA-measured ASMIs, regardless of age and obesity. The FFMI could be a useful simple surrogate marker of the ASMI for low muscle mass screen...
In Dutch breast cancer screening, solitary, new or growing well-circumscribed masses should be recalled for further assessment. This results in cancers detected but also in false positive recalls, esp...
A systematic literature search was performed using PubMed. In addition, follow-up data were retrieved on all 8860 recalled women in a Dutch screening region from 2014 to 2019....
Based on 15 articles identified in the literature search, we found that probably benign well-circumscribed masses that were kept under surveillance had a positive predictive value (PPV) of 0-2%. New o...
To recognize malignancies presenting as well-circumscribed masses, identifying solitary, new or growing lesions is key. This information is missing at initial screening since prior examinations are no...
Newborn screening (NBS) can prevent inborn errors of metabolism (IEMs), which may cause long-term disability and even death in newborns. However, in China, tandem mass spectrometry (MS/MS) screening h...
A Markov model was built to estimate the cost and quality-adjusted life-years (QALYs) of different screening programs. We compared PKU screening using traditional immunofluorescence (IF) with the othe...
The incremental cost-effectiveness ratio (ICER) of detecting all 12 IEMs in the national program is 277,823 RMB per QALY, below three times per capita GDP in Shenzhen. MS/MS screening in Shenzhen can ...
We conclude that the newborn screening using MS/MS in Shenzhen is cost-effective, and the budget affordable for the Shenzhen government. Two concepts for selecting the IEMs to be detected are also pre...
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease, highlighting the need for efficient screening strategies to identify patients with COPD. However, there is little e...
In this cross-sectional study, we originally investigated the efficacy of mass screening for COPD among community residents in the aforementioned region using two COPD screening questionnaires....
From July 2018 through January 2019, 688 participants were enrolled. COPD was diagnosed using the Global Initiative for the Chronic Obstructive Lung Disease criteria. Twenty-one patients were newly di...
Mass screening for COPD using screening questionnaires, particularly the COPD-PS questionnaire, might be useful to identify the early stages of COPD in a medical health check-up population....
Although the study design for identifying specific disease associations using a health insurance database has been well-established, few studies explore unknown comorbidities. We conducted a series of...
Gastric cancer is an inflammation-related cancer triggered by Helicobacter pylori infection. Understanding of the natural disease course has prompted the hypothesis that gastric cancer can be prevente...
The early detection of symptoms and rapid testing are the basis of an efficient screening strategy to control COVID-19 transmission. The olfactory dysfunction is one of the most prevalent symptom and ...
The main goal of this study was to examine the relationship between exposure to mass media health campaign massages and the uptake of non-communicable diseases (NCDs) screening services in Ghana and w...
Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of...
From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso. Individuals of all ages and genders who consented to participate were screened for viral ma...
A total of 15,650 participants were enrolled in the study. Of these, 51.4% were women and the age range was from 1 to 97 years. All participants were screened for HBsAg and 7,507 were also screened fo...
The prevalence of HBV and HCV infections remains high in Burkina Faso. Prevention strategies, including initial mass screening with rapid diagnostic tests and vaccination, need to be intensified....
